Arrowhead Pharmaceuticals
ARWR · Biotechnology
$58.02
0.6%Repligen
RGEN · Biotechnology
$176.93
1.0%The short version
- Arrowhead Pharmaceuticals is the larger business, with $829M of revenue in fiscal 2025 against $738M for Repligen.
- Arrowhead Pharmaceuticals grew revenue faster (23,258.2%, against 16.4%).
- Arrowhead Pharmaceuticals kept more of each dollar of sales as operating profit (11.9% operating margin, against 7.5% operating margin).
- Arrowhead Pharmaceuticals turned more of its sales into free cash flow (18.9% FCF margin, against 12.7% FCF margin).
| Latest fiscal year | ARWR · FY25 | RGEN · FY25 |
|---|---|---|
| Size | ||
| Market cap | $8.3B | — |
| Revenue | $829M | $738M |
| Free cash flow | $157M | $93.9M |
| Net income | −$1.6M | $48.9M |
| Growth | ||
| Revenue growth | 23,258.2% | 16.4% |
| 5-year growth | 56.6% | 15.1% |
| Share count change | 11.7% | — |
| Profitability | ||
| Gross margin | — | 52.3% |
| Operating margin | 11.9% | 7.5% |
| Net margin | −0.2% | 6.6% |
| FCF margin | 18.9% | 12.7% |
| Return on capital | — | 2.4% |
| Return on equity | −0.5% | 2.4% |
| Balance sheet | ||
| Net debt | −$665M | −$225M |
| Net debt / EBITDA | −5.5x | −1.7x |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | — | — |
| Piotroski F-score | 5 | — |
FY16
ARWR $0.2M
RGEN $105M
FY17
ARWR $31.4M
RGEN $141M
FY18
ARWR $16.1M
RGEN $194M
FY19
ARWR $169M
RGEN $270M
FY20
ARWR $88.0M
RGEN $366M
FY21
ARWR $138M
RGEN $671M
FY22
ARWR $243M
RGEN $802M
FY23
ARWR $241M
RGEN $632M
FY24
ARWR $3.6M
RGEN $634M
FY25
ARWR $829M
RGEN $738M
ARWR
RGEN
FY16
ARWR −51,627.1%
RGEN 15.3%
FY17
ARWR −117.8%
RGEN 9.9%
FY18
ARWR −346.5%
RGEN 13.4%
FY19
ARWR 36.3%
RGEN 13.4%
FY20
ARWR −105.9%
RGEN 19.1%
FY21
ARWR −107.8%
RGEN 24.9%
FY22
ARWR −73.4%
RGEN 28.0%
FY23
ARWR −85.2%
RGEN 7.5%
FY24
ARWR −16,927.1%
RGEN −5.5%
FY25
ARWR 11.9%
RGEN 7.5%
ARWR
RGEN
FY16
ARWR −$68.3M
RGEN $3.2M
FY17
ARWR −$31.9M
RGEN $12.0M
FY18
ARWR −$48.6M
RGEN $22.1M
FY19
ARWR $161M
RGEN $48.7M
FY20
ARWR −$108M
RGEN $40.2M
FY21
ARWR $148M
RGEN $51.9M
FY22
ARWR −$189M
RGEN $87.3M
FY23
ARWR −$331M
RGEN $77.7M
FY24
ARWR −$604M
RGEN $150M
FY25
ARWR $157M
RGEN $93.9M
ARWR
RGEN
FY16
ARWR —
RGEN 15.2%
FY17
ARWR −82.4%
RGEN 4.3%
FY18
ARWR −70.2%
RGEN 3.9%
FY19
ARWR 136.1%
RGEN 4.6%
FY20
ARWR −57.6%
RGEN 7.7%
FY21
ARWR −71.2%
RGEN 11.4%
FY22
ARWR −69.1%
RGEN 12.4%
FY23
ARWR −167.1%
RGEN 1.7%
FY24
ARWR —
RGEN −1.6%
FY25
ARWR —
RGEN 2.4%
ARWR
RGEN
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.